AbbVie Just Paid $10.9 Billion for This Tiny Biotech. Here’s Why.

Apogee Therapeutics surged 47% overnight on an all-cash buyout. Here’s what a 49% premium tells you about where pharma money is going. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  

June 23, 2026 AbbVie Just Paid $10.9 Billion for This Tiny Biotech. Here’s Why. Apogee Therapeutics (APGE) went to bed Friday at about $90 a share. It woke up Monday at $132 and change. AbbVie announced a $10.9 billion all-cash acquisition at $135.11 per share, a 49% premium. Both boards signed off unanimously. The target is zumilokibart, a late-stage IL-13 antibody for atopic dermatitis and asthma. AbbVie is spending $10.9 billion to build a Dupixent challenger. Dupixent generates over $14 billion a year. The math on why they wrote that check is not complicated. The deal signals something bigger about where large pharma is placing bets in 2026. The window between phase 2 data and a phase 3 readout is when these acquisitions happen. Watch Regeneron and Sanofi when the APG777 data lands. Read the full analysis › W.H. Insider: Trump Planning to Open $1 Trillion Gold Deposit Sponsored The gold price has skyrocketed over the last year. And according to Jim Rickards, the world’s #1 gold expert with close ties to the Trump White House, the president is currently planning a major gold play. An initiative that will unlock up to $1 TRILLION worth of gold over the next year. Today, Jim is revealing one of his favorite gold plays, 100% FREE. Click here to discover it. › You are receiving this e-mail at fromworksmart.jewelry@blogger.com, as part of your subscription to Money Morning. Manage Your Preferences by clicking here. No longer interested? Unsubscribe. © 2026 Money Morning. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before our subscribers have a fair opportunity to exit. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Agora Media, 14 West Mt Vernon Place, Baltimore, MD 21201. Money Morning is a First Light Financial, LLC publication. To contact us call 866-616-2166 or visit us online. Website  |  Privacy Policy  |  Terms & Conditions